Literature DB >> 26781233

Trends in cancer in the elderly population in Denmark, 1980-2012.

Marianne Ewertz1, Kaare Christensen2,3, Gerda Engholm4, Anne Mette T Kejs4, Lars Lund5, Lars E Matzen6, Per Pfeiffer1, Hans H Storm4, Jørn Herrstedt1.   

Abstract

BACKGROUND: Age is the strongest risk factor for developing cancer. The aim of the present analysis is to give an overview of the trends in cancer incidence, mortality, prevalence, and relative survival in Denmark from 1980 to 2012 focusing on age, comparing persons aged 70 years or more with those aged less than 70 years.
MATERIAL AND METHODS: Data derived from the NORDCAN database with comparable data on cancer incidence, mortality, prevalence and relative survival in the Nordic countries. The Danish data originate from the Danish Cancer Registry and the Danish Cause of Death Registry with follow-up for death or emigration until the end of 2013.
RESULTS: Incidence and mortality rates of all sites, but non-melanoma skin cancer, were higher and relative survival was lower among persons aged 70 years or more than those aged less than 70 years. The age distribution (age group-specific percentages of total number of incident cases) remained constant over time while the percentage of persons dying from cancer decreased with time up to the age of 79 years but increased for those aged 80 years or more, in whom about a third of all cancer deaths occurred in 2012. In 2003-2007, the five-year relative survival was 48% for men aged 70-79 years, 38% for men aged 80-89 years, and 29% for men aged 90 years or more and the corresponding figures for women were 46%, 39%, and 36%, respectively. There was a substantial increase in the number of prevalent cancer cases aged 70 years or older, especially among those aged 90 years or more.
CONCLUSION: An increase in elderly cancer patients is expected over the coming 20 years due to an increasing elderly population. Healthcare providers need to focus on developing specific strategies for treatment of elderly cancer patients in the future.

Entities:  

Mesh:

Year:  2016        PMID: 26781233     DOI: 10.3109/0284186X.2015.1114678

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

Review 1.  Cancer-Incidence, prevalence and mortality in the oldest-old. A comprehensive review.

Authors:  Shantell C Nolen; Marcella A Evans; Avital Fischer; Maria M Corrada; Claudia H Kawas; Daniela A Bota
Journal:  Mech Ageing Dev       Date:  2017-05-11       Impact factor: 5.432

2.  Incidence and mortality of corpus uteri cancer in China, 2008-2012.

Authors:  Yunfeng Xi; Wenrui Wang; Wenjie Chen; Ke Han; Liying Qiao; Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2019-06       Impact factor: 5.087

3.  Accuracy of an administrative database for pancreatic cancer by international classification of disease 10th codes: A retrospective large-cohort study.

Authors:  Young-Jae Hwang; Seon Mee Park; Soomin Ahn; Jong-Chan Lee; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2019-10-07       Impact factor: 5.742

4.  Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.

Authors:  Sidse Ehmsen; Anders Asmussen; Stefan S Jeppesen; Anna Christine Nilsson; Sabina Østerlev; Hanne Vestergaard; Ulrik S Justesen; Isik S Johansen; Henrik Frederiksen; Henrik J Ditzel
Journal:  Cancer Cell       Date:  2021-07-27       Impact factor: 31.743

5.  Outdoor work as a risk factor for high-grade cutaneous squamous cell carcinoma of the head and neck.

Authors:  Mateusz Szewczyk; Jakub Pazdrowski; Paweł Golusiński; Aleksandra Dańczak-Pazdrowska; Mariola Pawlaczyk; Jacek Sygut; Andrzej Marszałek; Wojciech Golusiński
Journal:  Postepy Dermatol Alergol       Date:  2018-08-21       Impact factor: 1.837

6.  How to estimate mortality trends from grouped vital statistics.

Authors:  Silvia Rizzi; Ulrich Halekoh; Mikael Thinggaard; Gerda Engholm; Niels Christensen; Tom Børge Johannesen; Rune Lindahl-Jacobsen
Journal:  Int J Epidemiol       Date:  2019-04-01       Impact factor: 7.196

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.